Drug intelligence / Profile preview

APP-401 + APP-069

Development stage: Preclinical
Lead developer: Aphios
Modality: Small Molecules

Overview

APP-401 + APP-069 is a combination of marine-derived small molecule therapeutics being developed by Aphios Corporation for the treatment of HIV/AIDS. These compounds were identified through high-throughput screening of over 10,000 marine microorganism fractions using cytoprotection and cytotoxicity assays. They are currently in preclinical development as anti-HIV leads. While they have demonstrated anti-viral activity in cell-based models, their specific molecular targets and chemical structures have not been publicly disclosed.

Beyond the preview

Go deeper on APP-401 + APP-069.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APP-401 + APP-069.

Explore the full profile